Carl Zeiss Meditec has strong fundamentals and growth potential. It has impressive free cash flow and rising shareholder ...

There's been a notable change in appetite for Carl Zeiss Meditec AG shares in the week since its yearly report, with the stock down 15% to €49.30. Revenues were €2.1b, approxi ...

Despite a challenging fiscal year, Carl Zeiss Meditec AG (CZMWF) leverages new product launches and strategic market ...

The broader Asia-Pacific region was also a weak spot, with organic growth in ophthalmology devices down 4.5% for the year, ...

EQS-News: Carl Zeiss Meditec AG / Key word (s): Annual Report/Annual Results Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue- Adjusted EBIT forecast achieved 11.12.2024 ...

Narrow-moat Carl Zeiss Meditec reported soft fourth-quarter earnings that came in lower than our expectations and ended the year on a soft note. Total sales of EUR 580 million during the quarter ...

RBC Capital analyst Jack Reynolds-Clark maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report) today and set a price target of €70.00. The company’s shares closed yesterday at €58.93.

ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex ...

ZEISS Canada is established in the market as a prominent leader in precision optics and innovative solutions and a trusted ...